Table 2.
Diagnostic accuracy of plasma and CSF biomarkers to detect amyloid-β positivity on PET or CSF amyloid-β42/40
| AUC | Accuracy | Sensitivity | Specificity | |
|---|---|---|---|---|
| Whole sample | ||||
| Plasma GFAP | 0.761 | 70.6% | 71.3% | 70.4% |
| CSF GFAP** | 0.694 | 60.1% | 81.2% | 51.8% |
| CSF sTREM2*** | 0.643 | 61.5% | 68.6% | 58.6% |
| CSF YKL-40 | 0.706 | 59.5% | 83.5% | 50.0% |
| All cognitively unimpaired individuals | ||||
| Plasma GFAP | 0.754 | 70.8% | 73.1% | 70.3% |
| CSF GFAP* | 0.675 | 66.0% | 67.3% | 65.7% |
| CSF sTREM2 | 0.699 | 61.8% | 78.9% | 58.1% |
| CSF YKL-40 | 0.735 | 57.5% | 88.5% | 50.6% |
| All cognitively impaired individuals | ||||
| Plasma GFAP | 0.779 | 70.9% | 71.4% | 70.4% |
| CSF GFAP* | 0.679 | 65.3% | 87.1% | 43.7% |
| CSF sTREM2** | 0.601 | 61.4% | 73.9% | 49.3% |
| CSF YKL-40** | 0.639 | 62.9% | 81.2% | 45.1% |
| Non-Alzheimer’s disease patients | ||||
| Plasma GFAP | 0.755 | 70.0% | 83.3% | 62.8% |
| CSF GFAP | 0.624 | 73.3% | 29.2% | 94.1% |
| CSF sTREM2 | 0.526 | 60.0% | 58.3% | 60.8% |
| CSF YKL-40* | 0.585 | 58.1% | 66.7% | 54.0% |
The analyses conducted in the whole sample, cognitively unimpaired and cognitively impaired individuals were performed using amyloid-β-PET, whereas the analyses conducted in a separate non-Alzheimer’s disease group were performed using CSF amyloid-β42/40.
*
P < 0.05 versus plasma GFAP.
**
P < 0.01 versus plasma GFAP.
***
P < 0.001 versus plasma GFAP.